2-(4-((tert-butyldimethylsilyl)oxy)phenyl)acetic acid | 114774-40-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-((tert-butyldimethylsilyl)oxy)phenyl)acetic acid
• 英文别名: 4-(tert-butyldimethylsiloxy)phenylacetic acid；4-(Dimethyl-tert-butylsilyloxy)phenylacetic acid；2-[4-[tert-butyl(dimethyl)silyl]oxyphenyl]acetic acid
• CAS: 114774-40-2
• 化学式: C₁₄H₂₂O₃Si
• 分子量: 266.412
• InChiKey: HFGPEISRKIZIHV-UHFFFAOYSA-N

物化性质

• 沸点：
  331.1±25.0 °C(Predicted)
• 密度：
  1.027±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-((tert-butyldimethylsilyl)oxy)phenyl)acetic acid 在 四丁基氟化铵 、 sodium hydride 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 40.08h， 生成 (4-(((4-(2-(((R,E)-4-((R)-1-(7-ethoxy-7-oxoheptyl)-5-oxopyrrolidin-2-yl)-1,1-difluoro-1-phenylbut-3-en-2-yl)oxy)-2-oxoethyl)phenoxy)carbonyl)amino)-1-hydroxybutane-1,1-diyl)diphosphonic acid
  参考文献：
  名称：

  Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis

  摘要：

  There is an important medical need for effective therapies to redress the general bone loss associated with advanced osteoporosis. Prostaglandin E-2 and related EP4 receptor agonists have been shown to stimulate bone regrowth but their use has been limited by systemic side effects. Herein is described the design and synthesis of novel dual-action bone-targeting conjugate pro-drugs where two classes of active agents, a bone growth stimulating prostaglandin E-2 EP4 receptor subtype agonist (5 or 6) and a bone resorption inhibitor bisphosphonate, alendronic acid (1), are coupled using metabolically labile carbamate or 4-hydroxyphenylacetic acid based linkers. Radiolabelled conjugates 9, 11a/b and 25 were synthesized and evaluated in vivo in rats for uptake of the conjugate into bone and subsequent release of the EP4 agonists over time. While conjugate 11a/b was taken up (9.0% of initial dose) but not released over two weeks, conjugates 9 and 25 were absorbed at 9.4% and 5.9% uptake of the initial dose and slowly released with half-lives of approximately 2 weeks and 5 days respectively. These conjugates were well tolerated and offer potential for sustained release and dual synergistic activity through their selective bone targeting and local release of the complimentary active components. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.01.024
• 作为产物：
  描述：

  4-羟基苯乙酸苄酯 在 palladium on activated charcoal 咪唑 、 氢气 作用下， 以 甲醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(4-((tert-butyldimethylsilyl)oxy)phenyl)acetic acid
  参考文献：
  名称：

  使用J anda J el™树脂固相合成低聚酯

  摘要：

  该通信描述了固相合成低聚酯的一般方法。将J anda J el™树脂与高度酸不稳定的Rink接头一起用作固体载体。使用缓冲试剂进行酯偶联反应，并将单体作为烯丙基酯进行保护。以这种方式，可以在基本上中性的条件下进行酯偶联和脱保护，从而以优异的收率和纯度产生产物。

  DOI：

  10.1016/s0040-4039(01)00172-1

文献信息

• SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS
  申请人：NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY

  公开号：US20190055249A1

  公开（公告）日：2019-02-21

  To obtain a novel therapeutic drug for a malignant tumor or fibrosis. Used is a compound represented by formula (1), a salt thereof, or a solvate thereof. Also used is a therapeutic drug for a malignant tumor or a therapeutic drug for fibrosis, comprising a compound represented by formula (1), a salt thereof, or a solvate thereof.

  为了获得一种用于恶性肿瘤或纤维化的新型治疗药物。使用的是由式（1）表示的化合物，其盐或溶剂化物。还使用了一种用于恶性肿瘤或纤维化的治疗药物，包括由式（1）表示的化合物，其盐或溶剂化物。
• Deoxyfluorination with CuF ₂ : Enabled by Using a Lewis Base Activating Group
  作者：D. Eilidh Sood、Sue Champion、Daniel M. Dawson、Sonia Chabbra、Bela E. Bode、Andrew Sutherland、Allan J. B. Watson

  DOI：10.1002/anie.202001015

  日期：2020.5.25

  Deoxyfluorination is a primary method for the formation of C-F bonds. Bespoke reagents are commonly used because of issues associated with the low reactivity of metal fluorides. Reported here is the development of a simple strategy for deoxyfluorination, using first-row transition-metal fluorides, and it overcomes these limitations. Using CuF2 as an exemplar, activation of an O-alkylisourea adduct

  脱氧氟化是形成CF键的主要方法。由于金属氟化物的低反应性相关的问题，通常使用定制试剂。本文报道了使用第一行过渡金属氟化物开发一种简单的脱氧氟化策略的方法，它克服了这些限制。使用CuF2作为示例，原位形成的O-烷基异脲加合物的活化可以有效地将亲核氟化物转移到一系列伯醇和仲醇中。光谱研究已被用来探测 反应性增强的起源。还介绍了该方法在实现18 F放射性标记方面的实用性。
• Antihypercholesterolemic compounds
  申请人：Merck & Co., Inc.

  公开号：US04876366A1

  公开（公告）日：1989-10-24

  Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1## and pharmaceutically acceptable salts of the compounds (II) in which Z is hydrogen are disclosed.

  新型3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂，可用作抗高胆固醇药物，其一般结构式（I）和（II）如下所示：##STR1##以及其中Z为氢的化合物（II）的药用盐被披露。
• PIDA-Mediated Rearrangement for the Synthesis of Enantiopure Triazolopyridinones
  作者：Zenghui Ye、Hong Zhang、Na Chen、Yanqi Wu、Fengzhi Zhang

  DOI：10.1021/acs.orglett.0c02278

  日期：2020.8.21

  oxidative cyclization/1,2-carbon migration of hydrazides for the synthesis of otherwise inaccessible hindered or enantiopure triazolopyridinones has been developed. This protocol exhibits broad substrate scope and can be easily scaled up by continuous flow synthesis under mild conditions. Most importantly, this method demonstrates a rearrangement with retention of configuration and can be readily applied

  已经开发了酰肼的串联氧化环化/ 1,2-碳迁移，用于合成否则无法获得的受阻或对映纯三唑并吡啶并酮。该方案具有广泛的底物范围，可以通过在温和条件下进行连续流合成轻松地扩大规模。最重要的是，该方法显示了重排并保留了构型，可以很容易地应用于含羧酸的药物，氨基酸和天然产物的后期修饰，以得到对映纯的三唑并吡啶并酮。
• COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES
  申请人：JNC Corporation

  公开号：US20140316137A1

  公开（公告）日：2014-10-23

  Coelenterazine analogs with different luminescence properties from conventional ones and coelenteramide analogs with different fluorescence properties from conventional ones have been desired. The invention provides coelenterazine analogs modified at the 8-position of coelenterazine and coelenteramide analogs modified at the 2- or 3-position of coelenteramide.

  寻求具有不同发光特性的螅螅素类似物和具有不同荧光特性的螅螅酰胺类似物已经被期望。该发明提供了在螅螅素的8位进行改性的螅螅素类似物，以及在螅螅酰胺的2位或3位进行改性的螅螅酰胺类似物。